Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04729621 · ClinicalTrials.gov registry record · Phase 3
A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis
A Phase 3 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 3
- Development phase
- 332
- Enrollment target
NCT04729621: Completed Phase 3 study, sponsored by Teva Pharmaceuticals USA.
NCT04729621 is a Phase 3 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 332 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04729621, a Phase 3 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 332 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate similar efficacy and safety between TVB-009 and Prolia® (denosumab)
Interventions
- COMBINATION_PRODUCT TVB-009
- COMBINATION_PRODUCT Prolia®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 332 participants |
| Start Date | 2021-03-22 |
| Est. Completion | 2023-06-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04729621
The ClinicalTrials.gov registry entry for NCT04729621 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 332 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TVB-009 is the first listed.
NCT04729621 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04729621 about?
NCT04729621 is a clinical study titled "A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis". The purpose of this study is to demonstrate similar efficacy and safety between TVB-009 and Prolia® (denosumab)
What is the current status of trial NCT04729621?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 332 participants. The study started on 2021-03-22. Estimated completion is 2023-06-19.
What interventions are being tested in trial NCT04729621?
The interventions under investigation include: TVB-009 (COMBINATION_PRODUCT), Prolia® (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04729621?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.